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Abstract
Background—Airways inflammation is a
feature of chronic obstructive pulmonary
disease (COPD), but the role of cortico-
steroids in the management of clinically
stable patients has yet to be established. A
randomised controlled study was carried
out to investigate the eVect of high dose
inhaled beclomethasone dipropionate
(BDP) administered for two months to
patients with stable, smoking related
COPD. Sputum induction was used to
evaluate bronchial inflammation re-
sponse.
Methods—34 patients (20 men and 14
women) were examined on three separate
occasions. At the initial clinical assess-
ment (visit 0), spirometry and blood gas
analysis were performed. On visit 1
(within one week of visit 0) sputum induc-
tion was performed and each patient was
randomised to receive either BDP 500 µg
three times daily (treated group) or noth-
ing (control group). After two months
(visit 2), all patients underwent repeat
clinical assessment, spirometry, and spu-
tum induction.
Results—There were no diVerences in
sputum cell counts between the groups at
baseline. After two months of treatment,
induced sputum samples from patients in
the treated group showed a reduction in
both neutrophils (−27%) and total cells
(−42%) with respect to baseline, while the
control group did not (neutrophils +9%,
total cells +7%). Macrophages increased
in the treated group but not in the control
group. The mean final value of sputum
neutrophils was 52% in the treated group
and 73.3% in the control group (95% con-
fidence interval (CI) −27.2 to −15.4). The
mean final value of sputum macrophages
was 35.8% in treated group and 19.3% in
control group (95% CI 10.3 to 22.8). The
diVerences between the treated and con-
trol groups for neutrophils (−21.3%),
macrophages (+16.5%), and total cells
(−65%) were significant. Spirometry and
blood gas data did not change from
baseline in either patient group.
Conclusions—A two month course of
treatment with high dose inhaled BDP
reduces significantly neutrophil cell
counts in patients with clinically stable,
smoking related COPD. Further studies
on the eVectiveness of inhaled steroids in
COPD are needed to confirm the clinical
importance of this observation.
(Thorax 1998;53:583–585)
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The value of corticosteroids in the manage-
ment of clinically stable chronic obstructive
pulmonary disease (COPD) has yet to be
established.1 2 In particular, there is very little
evidence to date on the eVect of inhaled
steroids in this disease.3 4
Our study aimed to evaluate, using sputum
induction,5 the eVects of two months of inhaled
high dose (1500 µg/day) beclomethasone
dipropionate (BDP) on bronchial inflamma-
tion in patients with stable, mild to moderate
COPD related to smoking.
Methods
SUBJECTS
We recruited 34 patients (20 men and 14
women, aged 53 to 71 years) with stable
COPD from the outpatient clinic of the Crema
Hospital. Clinically stable COPD was diag-
nosed according to a recent European consen-
sus conference.6 Patients were smokers who
refused or failed a programme to quit smoking.
During the course of the study, the subjects
were asked to continue smoking the same
number of cigarettes each day as at the time of
Table 1 Characteristics of COPD patients at baseline
Treated group Control group
Sex (M/F) 11/6 9/8
Age (years) 58 (6) 57 (4)
Smoking (packs/year) 50 (7) 48 (8)
FEV1 (% predicted) 60.2 (9) 59.1 (9)
FEV1/VC(%) 68 (3) 65 (6)
PaO2 (mm Hg) 71.9 (5.8) 69.7 (3.8)
PaCO2 (mm Hg) 39.2 (3.5) 38.6 (5.2)
Data are presented as mean (SE).
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entry. Patients who had taken inhaled or oral
steroids or had suVered a respiratory tract
infection in the previous three months were
excluded. None of the patients was taking
theophyllines, or oral or long acting inhaled â2
agonists. All subjects gave written informed
consent to participate in the study, which was
approved by the local ethics committee. We
compared sputum cell counts of COPD
patients with those of 16 healthy non-atopic
volunteers, age matched with the subjects in
the investigation. All the healthy subjects were
asymptomatic lifelong non-smokers with nor-
mal spirometry.
STUDY DESIGN
The study was a randomised, controlled, open
study. The clinical part of the study was open,
but all diVerential cell counting was carried out
in a double blind fashion. Subjects were exam-
ined on three separate days. At the initial clini-
cal assessment (visit 0), spirometry plus formal
testing for reversibility, and blood gas analysis
were performed. At visit 1 (within one week of
visit 0) each patient was randomised to receive
either BDP 500 µg three times daily (treated
group) or no treatment (control group).
Sputum induction was also carried out. All
patients were reviewed after eight weeks for
repeat clinical assessment, spirometry, blood
gas analysis, and sputum induction (visit 2).
SPUTUM INDUCTION
Inhalation procedure
Forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC) were
measured before and 10 minutes after inhaled
salbutamol (two puVs; 200 µg). Subjects then
inhaled hypertonic (4.5%) saline nebulised by
an ultrasonic device (De Vilbiss 65, DeVilbiss
Corporation, Somerset, Pennsylvania, USA)
for increasing time periods—one, two, four,
eight, and 16 minutes. FEV1 measurements
were repeatedly taken one minute after each
inhalation period.
Sputum processing
Sputum samples were examined within two
hours. Sputum quality was assessed, selected
portions of the sputum sample were chosen,
total cell counts were performed, and cytospins
prepared using previously described methods.7
Samples were discarded if viability levels were
50% or less, or squamous contamination was
20% or more, or both. An overall diVerential
cell count on 500 nucleated non-squamous
cells was performed by two examiners and
results reported as mean of the two counts. All
sputum counts and measurements were per-
formed blind to the clinical details.
DATA ANALYSIS
Group data were expressed as mean (SE).
Between group changes in cell counts were
compared with theMann-Whitney U test and a
95% confidence interval (CI). Between group
diVerences, with regard to blood gas and
spirometry data, were subjected to unpaired t
test. Statistical significance was defined as
p<0.05.
Results
There were no significant diVerences between
the treated and control groups of the COPD
patients with regard to age, smoking history,
blood gas, and spirometry (table 1). None of
the COPD patients was unable to produce
adequate sputum samples or stopped the
procedure because of a fall in FEV1 or worsen-
ing of symptoms. The coeYcient of variability
of duplicate counts was less than 6% with a
degree of correlation greater than 0.8. The
percentage of neutrophils in the sputum of the
COPD patients was significantly higher than in
the healthy subjects’ sputum (treated group 73
(3); control group 71 (4); healthy subjects 29
(18); p<0.05). There was no diVerence in the
sputum cell counts at baseline between the
treated and control groups of the COPD
patients (table 2).
After two months of treatment with BDP,
induced sputum samples from the treated
patients showed a reduction from baseline of
both neutrophils (fig 1) and total cells (table 2).
Table 2 Induced sputum cellularity results, spirometric data, and blood gas analysis in the
BDP treated patients and controls
BDP Controls
Before After Before After
Cells/ml (× 104) 240 (46) 139 (63) 198 (31) 204 (39)
Neutrophils (%) 73.4 (2.6) 52.0 (1.8) 71.4 (3.7) 73.3 (2.2)
Eosinophils (%) 3.5 (1.0) 3.1 (0.8) 2.0 (0.4) 2.4 (0.5)
Lymphocytes (%) 3.8 (0.8) 3.9 (0.7) 2.0 (0.2) 2.2 (0.9)
Macrophages (%) 19.6 (1.9) 35.8 (2.1) 21.7 (3.6) 19.3 (2.2)
Epithelial cells (%) 1.1 (0.1) 2.3 (0.3) 1.5 (0.2) 2.0 (0.3)
Viability (%) 84 (5) 81 (8) 79 (8) 86 (5)
Squamous cells (%) 7 (1) 8 (2) 9 (2) 6 (3)
FEV1 (% predicted) 60.2 (9) 58.2 (10) 59.1 (9) 54.4 (8)
FVC (% predicted) 76 (12) 74 (14) 83 (7) 76 (9)
PaO2 (mm Hg) 71.9 (5.8) 75.0 (6.2) 69.7 (3.8) 70.3 (4.3)
PaCO2 (mm Hg) 39.2 (3.5) 36.8 (3.9) 38.6 (5.2) 37.3 (3.2)
Values are mean (SE).
Table 3 Sputum cell counts for treatment and placebo groups, and diVerence between the groups at visit 2
BDP Controls
Mean
diVerence
between
groups 95% CI
Mean (SE)
absolute value
Mean
diVerence from
baseline
Mean (SE)
absolute value
Mean
diVerence from
baseline
Cells/ml (× 104) 139 (63) −101 204 (39) 6 −65* −187 to −26
Neutrophils (%) 52.0 (1.8) −21.4 73.3 (2.2) 1.9 −21.3* −27.2 to −15.4
Eosinophils (%) 3.1 (0.8) −0.4 2.4 (0.5) 0.4 0.7 −4.21 to 5.57
Lymphocytes (%) 3.9 (0.7) 0.1 2.2 (0.9) 0.2 1.7 −0.34 to 2.67
Macrophages (%) 35.8 (2.1) 16.2 19.3 (2.2) −2.4 16.5* 10.3 to 22.8
Epithelial cells (%) 2.3 (0.3) 1.2 2.0 (0.3) 0.5 0.3 −0.69 to 1.22
Viability (%) 81 (8) −3 86 (5) 7 −5 −8.25 to 0.72
Squamous cells (%) 8 (2) 1 6 (3) −3 2 −0.47 to 4.47
*p < 0.05.
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There was little diVerence in total and
diVerential cell counts in the control group at
the end of the study compared to baseline val-
ues. Sputum macrophages increased only in
the treated group (table 2).
The mean final value of sputum neutrophils
was 52.0% in the treated group and 73.3% in
control group (95% CI −27.2 to −15.4). The
mean final value of sputum macrophages was
35.8% in the treated group and 19.3% in the
control group (95% CI 10.3 to 22.8). At the
end of the study the diVerences between the
treated and control groups for neutrophils
(−21.3%), macrophages (+16.5%), and total
cells (−65%) were significant (p<0.05) (table
3).
FEV1, FVC, PaO2, and PaCO2 did not
change from baseline in either group (table 2).
Discussion
Our study aimed to evaluate, by sputum
induction, the eVect of two months of inhaled
high dose BDP (1500 µg/day) on bronchial
inflammation in stable patients with COPD.
We found that the proportion of neutrophils
and the number of neutrophils present in
induced sputum samples decreased over two
months in patients receiving the high dose of
inhaled BDP. Our findings are supported by
Llewellyn Jones et al who also treated COPD
subjects with inhaled steroids (in a double
blind manner) for several months.3 That study
showed a small but significant reduction in the
chemotactic activity of the secretions which
would be consistent with a decrease in
subsequent neutrophil recruitment.
Keating et al, however, found no significant
anti-inflammatory eVect of inhaled steroids in
COPD patients treated over two weeks.4 It is
highly likely that a longer period of treatment is
important in a condition such as COPD, which
has low grade inflammation, rather than a more
acute disease like asthma.8 In our study inhaled
BDP did not change the results of lung
function tests and this is consistent with the
patient population being studied. Renkema et
al showed that budesonide 1600 µg daily
slowed down the rate of lung function decline
in patients with stable COPD during two years
of treatment.9 This suggests that a reduction in
airway inflammation might influence lung
function decline only over a long period of
treatment with inhaled corticosteroids. This
hypothesis is supported by Stanescu et al who
evaluated induced sputum cellularity in smok-
ers over 15 years.10 They showed that airways
obstruction and chronic expectoration, as well
as accelerated decline in lung function, are
associated with increased number of neu-
trophils in the sputum.
In summary, our results support the hypoth-
esis that inhaled steroids might be beneficial in
treating stable COPD, leading to a decrease in
bronchial neutrophilic inflammation. Further
double blind, placebo controlled studies are
needed to confirm our observations.
1 Van Schayck CP, Van Grunsven PM, Dekhuijzen PN. Do
patients with COPD benefit from treatment with inhaled
corticosteroids? [editorial]. Eur Respir J 1996;9:1969–70.
2 De Guia TS. Inhaled corticosteroids in COPD. A light at
the end of the tunnel? [editorial]. Chest 1995;108:1486–7.
3 Llewellyn Jones CG, Harris TAJ, Stockley RA. EVect of flu-
ticasone propionate on sputum of patients with chronic
bronchitis and emphysema. Am J Respir Crit Care Med
1996;153:616–21.
4 Keatings VM, Jatakanon A, Worsdell YM, et al. EVects of
inhaled corticosteroids on inflammatory indices in asthma
and COPD. Am J Respir Crit Care Med 1997;155:542–8.
5 Pavord ID, Pizzichini MMM, Pizzichini E, et al. The use of
induced sputum to investigate airway inflammation.Thorax
1997;52:498–501.
6 Siafakas NM, Vermeire P, Pride NB, et al. Optimal
assessment and management of chronic obstructive
pulmonary disease (COPD). Eur Respir J 1995;8:1398–
420.
7 Spanevello A, Migliori GB, Sharara AM, et al. Induced spu-
tum to assess airway inflammation: a study of
reproducibility. Clin Exp Allergy 1997;27:1138–44.
8 Chanez P, Vignola AM, O’Shaugnessy T, et al. Corticoster-
oid reversibility in COPD is related to features of asthma.
Am J Respir Crit Care Med 1997;155:1529–34.
9 Renkema TEJ, Schouten JP, Koëter GH, et al. EVects of
long-term treatment with corticosteroids in COPD. Chest
1996;109:1156–62.
10 Stanescu D, Sanna A, Veriter C, et al. Airways obstruction,
chronic expectoration, and rapid decline of FEV1 in smok-
ers are associated with increased levels of sputum
neutrophils. Thorax 1996;51:267–71.
Figure 1 Sputum total neutrophil counts before and after
two months of treatment with inhaled steroid
(beclomethasone dipropionate) (A) or no treatment (B).
Between group comparison of neutrophil counts was
significantly diVerent (p<0.05).
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